Loading...
XLON
HIK
Market cap5.94bUSD
Jul 25, Last price  
2,004.00GBP
1D
-1.18%
1Q
5.53%
Jan 2017
5.86%
IPO
610.64%
Name

Hikma Pharmaceuticals PLC

Chart & Performance

D1W1MN
P/E
1,653.59
P/S
189.84
EPS
1.63
Div Yield, %
3.09%
Shrs. gr., 5y
-1.66%
Rev. gr., 5y
7.22%
Revenues
3.13b
+8.77%
262,215,000317,022,000448,796,000580,656,000636,884,000730,936,000918,025,0001,108,721,0001,365,000,0001,489,000,0001,440,000,0001,950,000,0001,936,000,0002,070,000,0002,207,000,0002,341,000,0002,553,000,0002,517,000,0002,875,000,0003,127,000,000
Net income
359m
+88.95%
43,867,00054,522,00062,576,00057,125,00077,683,00098,849,00080,107,000100,320,000212,000,000278,000,000252,000,000155,000,000-843,000,000282,000,000486,000,000431,000,000421,000,000188,000,000190,000,000359,000,000
CFO
564m
-7.24%
32,713,00029,992,00043,117,00057,872,000105,518,000138,786,000102,639,000182,161,000337,000,000425,000,000366,000,000293,000,000443,000,000430,000,000472,000,000464,000,000638,000,000530,000,000608,000,000564,000,000
Dividend
Aug 15, 202424.73536 GBP/sh
Earnings
Aug 06, 2025

Profile

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including anti-infective, cardiovascular, central nervous system, diabetes, oncology, pain management, and respiratory. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.
URL
https://www.hikma.com/
IPO date
Nov 01, 2005
Employees
8,700
Domiciled in
GB
Incorporated in
GB

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
3,127,000
8.77%
2,875,000
14.22%
2,517,000
-1.41%
Cost of revenue
2,515,000
2,249,000
1,905,000
Unusual Expense (Income)
NOPBT
612,000
626,000
612,000
NOPBT Margin
19.57%
21.77%
24.31%
Operating Taxes
93,000
89,000
42,000
Tax Rate
15.20%
14.22%
6.86%
NOPAT
519,000
537,000
570,000
Net income
359,000
88.95%
190,000
1.06%
188,000
-55.34%
Dividends
(175,000)
(137,000)
(125,000)
Dividend yield
3.93%
3.44%
3.58%
Proceeds from repurchase of equity
(38,000)
971,000
BB yield
0.85%
-27.81%
Debt
Debt current
653,000
161,000
148,000
Long-term debt
710,000
1,096,000
1,144,000
Deferred revenue
1,055,000
Other long-term liabilities
181,000
102,000
(1,074,000)
Net debt
1,088,000
963,000
948,000
Cash flow
Cash from operating activities
564,000
608,000
530,000
CAPEX
(165,000)
(169,000)
(138,000)
Cash from investing activities
(381,000)
(333,000)
(607,000)
Cash from financing activities
(188,000)
(337,000)
(58,000)
FCF
298,000
510,000
608,000
Balance
Cash
213,000
229,000
292,000
Long term investments
62,000
65,000
52,000
Excess cash
118,650
150,250
218,150
Stockholders' equity
2,413,000
2,209,000
2,145,000
Invested Capital
3,689,350
3,351,750
3,231,850
ROIC
14.74%
16.31%
18.21%
ROCE
16.07%
17.88%
17.64%
EV
Common stock shares outstanding
223,493
222,369
225,000
Price
19.93
11.40%
17.89
15.27%
15.52
-30.06%
Market cap
4,454,222
11.97%
3,978,176
13.92%
3,492,000
-32.46%
EV
5,553,222
4,952,176
4,732,000
EBITDA
809,000
816,000
794,000
EV/EBITDA
6.86
6.07
5.96
Interest
75,000
90,000
77,000
Interest/NOPBT
12.25%
14.38%
12.58%